Storyline
MSD partners with Quotient Therapeutics in $2.2 billion deal for IBD drug targets
Merck Sharp & Dohme (MSD) has entered a $2.2 billion agreement with Flagship Pioneering's Quotient Therapeutics to access its somatic genomics platform for discovering new drug targets in inflammatory bowel disease (IBD).
Evidence locked
Today's free sample is only available for the edition's flagship storyline.
Evidence preview
- MSD taps Quotient for IBD drug targets in $2.2bn dealpharmaphorum
- Merck pays $20M upfront for Quotient’s genomics platform in IBD dealFierce Biotech